JPH08509459A - Stabilized medical aerosol solution formulation - Google Patents
Stabilized medical aerosol solution formulationInfo
- Publication number
- JPH08509459A JPH08509459A JP6514292A JP51429294A JPH08509459A JP H08509459 A JPH08509459 A JP H08509459A JP 6514292 A JP6514292 A JP 6514292A JP 51429294 A JP51429294 A JP 51429294A JP H08509459 A JPH08509459 A JP H08509459A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- aerosol solution
- formulation
- aerosol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】 安定化医用エアーゾル溶液製剤 本願は、出願番号第07/987,852(出願日1992年12月9日)の一部継続出願であ る。 本発明は、エアーゾル投与に好適な安定した医薬溶液製剤に関する。特に、本 発明は、噴射剤として環境に安全なヒドロフルオロカーボン(HFC)を、補助 溶剤としての有機化合物と共に有する、溶液に薬剤を含むエアーゾル溶液製剤に 、無機酸又は有機酸を添加した、エアーゾル投与に好適な安定した医薬溶液製剤 に関する。この酸は、薬剤と溶液製剤中に存在する補助溶剤及び/又は水とが相 互作用することから主として生じる薬剤の崩壊又は分解に対して、酸は安定性を もたらす。発明の背景 圧縮化、計量服用吸入器(MDI)によって薬剤のエアーゾル製剤を投与する ことが、閉塞性気道症及び喘息のような治療法に広く用いられている。経口投与 と比較すると、吸入では、全身性副作用を最小化しながら、作用の始まりをより 速くする。エアーゾル製剤は口からの吸入によって、又は鼻の粘膜への塗布によ って投与することができる。 MDIによるエアーゾル投与のための製剤は溶液又は懸濁液とすることができ る。溶液製剤は、薬剤及び賦形剤が噴出溶剤に完全に溶解する性質により、均一 になるという利点をもたらす。また、溶液製剤は懸濁液製剤に伴う物理的安定性 の問題を未然に防いで、界面活性剤の必要性を除去しつつ、より矛盾のない均一 量での投与を保証する。 MDIによるエアーゾル溶液製剤の投与は、その製造に用いた噴射剤系の噴射 力に依存する。従来、噴射剤は、クロロフルオロカーボン(CFC)混合物を含 有し、所望の溶解度、気圧、及び製剤の安定性をもたらした。しかし、最近、C FCは地球のオゾン層の枯渇に貢献するので環境に害を及ぼすと確証されたため 、エアーゾル吸入製剤中、環境に害を及ぼすCFC噴射剤に代わって、環境に 安全なヒドロフルオロカーボン(HFC)噴射剤又は他の非塩素化噴射剤に置き 換えることが望ましい。例えば、米国特許第4,174,295号には、ヘアーラッカー 、耐汗性製品、香料、消臭剤、塗料、殺虫剤などの家庭製品の分野の応用に好適 な、HFCの組合せ(これには飽和炭化水素成分も含めることができる)からな る噴射剤系の使用について開示されている。 あるHFCが、薬剤のエアー投与の噴射剤として用いるのに好適な特性を有す ることが当業界で知られている。例えば、公開欧州特許出願第0 372 777号(EP0 89312270.5)には、1,1,1,2-テトラフルオロエタン(HFC-134(a))を少なくとも 1つの『補助剤』(HFC-134(a)より極性が大きい化合物)及び界面活性剤と組合 わせて用いて、エアーゾル経路による投与に好適な、薬剤の懸濁液及び溶液製剤 を調製することが記載されている。また、PCT国際公開出願WO91/11496号(PCT/E P91/00178)には、薬剤の懸濁液エアーゾル製剤を調製するのに有用な、1,1,1,2 ,3,3,3-ヘプタフルオロプロパン(HFC-227)の使用(任意に他の噴出剤と混合し てもよい)について記載されている。 エアーゾル溶液製剤にHFC及び補助溶剤を含む噴出剤系を用いると、前には 認識されていなかったか、又は先行技術では解決されなかった化学的安定性の問 題が存在するということが今や見出された。これは、そのようなHFC噴出剤/ 補助溶剤系において、薬剤がその系内に存在する補助溶剤及び/又は水と相互作 用して、生成物の分解又は崩壊をもたらし得ることによるものである。無機酸又 は有機酸のいずれかの酸をHFC噴出剤/補助溶剤系に添加することにより、薬 剤に必須の化学的安定性をもたらすということがさらに見出された。本発明の説明 『エアーゾル懸濁液製剤』の語は、薬剤が微細粒子の形態で賦形剤中に懸濁す る、エアーゾル投与に好適な薬剤の医薬製剤を意味する。 『エアーゾル溶液製剤』の語は、薬剤及び賦形剤が完全に溶解した、エアーゾ ル投与に好適な薬剤の医薬製剤を意味する。 『安定化エアーゾル溶液製剤』の語は、時間により実質的に化学的安定性を示 すエアーゾル溶液製剤を意味する。 臭化イプラトロピウムは、商標『アトロベント(ATROVENT)』で市場に出てい る抗コリン作用性気管支拡張薬である。この薬剤は、噴出剤としてのCFC(ジ クロロジフルオロメタン、ジクロロテトラフルオロエタン、及びトリクロロモノ フルオロメタン)と大豆レシチンとの混合物を含む、エアーゾル懸濁液製剤とし て投与する。 HFC-134(a)、エタノール、及び無機酸又は有機酸のいずれかを含む均一系に 臭化イプラトロピウムを溶解することにより、臭化イプラトロピウムの安定化エ アーゾル溶液製剤を得ることができることが研究によって示された。あるタイプ で、かつある量の酸を系に添加することにより、安定な溶液製剤を得るために重 要である酸性のレベルを明確にすることができるであろう。 このように、本発明は、薬剤、HFC噴出剤、補助溶剤、及び無機酸又は有機 酸を含有する安定化エアーゾル溶液製剤を提供する。少量の水(重量で約5%ま で)が噴出剤/補助溶剤系に存在していてもよい。 好適なHFC噴出剤は、補助溶剤と混合したとき、治療上有効量の薬剤が溶解 することができる均一な噴出剤系を形成するものである。HFC噴出剤は毒物学 的に安全でなければならず、かつ圧縮化MDIによって薬剤を投与できるように 好適な気圧を有しなければならない。さらに、HFC噴出剤は、薬剤を投与する のに用いるMDI装置の成分(容器、バルブ、及びシーリング・ガスケットなど のようなもの)に受け入れられるものでなければならない。好ましいHFC噴出 剤として、1,1,1,2-テトラフルオロエタン(HFC-134(a))及び1,1,1,2,3,3,3-ヘ プタフルオロプロパン(HFC-227)がある。HFC-134(a)が特に好ましい。HF C噴出剤の他の例として、HFC-32(ジフルオロメタン)、HFC-143(a)(1,1,1- トリフルオロエタン)、HFC-134(1,1,2,2-テトラフルオロエタン)、及びHFC-1 52a(1,1-ジフルオロエタン)が挙げられる。 本発明において、HFC噴出剤の代わりに非ハロゲン化炭化水素噴出剤を用い ることができることは当業者にとって明らかであろう。非ハロゲン化炭化水素の 例として、プロパン、n-ブタン、及びイソブタンを含む飽和炭化水素、並びにジ エチルエーテルを含むエーテルが挙げられる。 HFC噴出剤を1つだけ用いることが好ましいが、2以上のHFC噴出剤の混 合物、又はHFC噴出剤を少なくとも1つと1以上の非CFC噴出剤との混合物 を本発明のエアーゾル溶液製剤に用いることができるということも当業者にとっ て明らかであろう。 実質的に非水性HFC噴出剤/補助溶剤系が好ましい。水は、HFC噴出剤/ 補助溶剤系の不純物として少量存在してもよく、製造工程で導入されてもよく、 又は、バルブ又はバルブ/容器シール又はガスケットから系中へ浸透してもよい 。所望により、少量の水を、例えば製造を援助するために、HFC/噴出剤系に 添加してもよい(重量で約5%まで)。 所望であれば、医薬として許容される賦形剤を、本発明のエアーゾル溶液製剤 に含んでいてもよい。例えば、製剤のエアーゾル投与に用いるMDI装置に使用 するバルブ系の性能を向上させるために、溶解性界面活性剤を添加してもよい。 好ましい界面活性剤の例として、オレイン酸、トリオレイン酸ソルビタン、レシ チン、及びミリスチン酸イソプロピルが挙げられる。他の好適な潤滑剤は当業界 で既知のものである(例えば、公開欧州特許出願第0372777号(EPO893122705) を参照のこと)。他の賦形剤として、(a)酸化防止剤、例えばアスコルビン酸 及びトコフェロール;(b)味マスキング剤、例えばメンソール、甘味料、及び 人工又は天然調味料;及び(c)圧力調節剤、例えばn-ペンタン、イソペンタン 、ネオペンタン、及びn-ヘキサンが挙げられる。 本発明に用いる薬剤は、MDI又は同様の装置からのエアーゾル投与に好適な 、いかなる物質であってもよい。薬剤はHFC噴出剤/補助溶剤系に溶解しなけ ればならず、かつ、HFC噴出剤/補助溶剤系中で重要となる崩壊又は分解を特 徴的に示さなければならない。崩壊又は分解の速度が酸を添加することによって 有効に遅延させることができるように、薬剤の崩壊又は分解が酸に敏感でなけれ ばならない。 薬剤の分解又は崩壊はさまざまな化学的機構によって生じ、最も重要なのは薬 剤と補助溶剤又は系中に存在する水との相互作用であり、加水分解、エステル化 、及び/又は他の生成物を形成する。 本発明のエアーゾル溶液製剤中の薬剤の量は、意図する治療効果をもたらすの に有効な量、即ち、製剤の1以上の計量体積が薬剤の有効量となるであろう量で ある。エアーゾル溶液製剤に用いる特定の薬剤の有効性は製剤中の薬剤の量で決 まることは当業者にとって明らかであろう。一般に、薬剤は、製剤の全重量の約 0.001〜10重量パーセントの量で存在する。製剤の全重量の約0.01〜1 .0重量パーセントの量が好ましい。 気管支拡張薬(特に抗コリン作用性及び交感神経作用性)が、本発明のエアー ゾル溶液製剤に用いるのに好ましい薬剤の分類である。当業者は、一般に他の分 類の薬剤も用いることができることを認識しているであろう。そのような分類の 例として、抗ヒスタミン薬、抗アレルギー剤、抗炎症薬、PAF拮抗薬、鎮咳薬 、抗生物質、肥満細胞安定剤、粘液溶解薬、抗腫瘍薬、抗感染症薬、ワクチン、 麻酔薬、診断用薬、鎮痛剤、抗狭心症剤、ロイコトリエン拮抗薬、及び5-リポキ シゲナーゼ拮抗薬が挙げられる。薬剤には、ホルモン、酵素、タンパク質、ペプ チド、ステロイド、アルカロイド、又はこれらの組合せを含み、それには限定さ れないさまざまなタイプの有機分子も挙げることができる。 本発明のエアーゾル溶液製剤に用いる薬剤の最も好ましい例は、臭化イプラト ロピウムである。他の好ましい例には、臭化オキシトロピウム(oxitropium bro mide)(BA253)、アルブテロール(albuterol)、硫酸メタプラテレノール(me tapraterenol sulfate)、臭化チオトロピウム(tiotropium bromide)(BA-679 )、8-アゾニアビシクロ[3.2.1]オクト−6-エン(8-azoniabicyclo[3.2.1]oct -6-ene)、3-[(ヒドロキシジ−2-チエニルアセチル)オキシ]-8,8-ジメチル −(3-[(hydroxydi-2-thienylacetyl)oxy]-8,8-dimethyl-)、クロリド(chlori de)、エンド-(BEA 2108 CL)(endo-(BEA 2108 CL))、及び臭化水素酸フェノ テロールが挙げられる。 薬剤の他の例として次のものが挙げられる。交感神経作用性気管支拡張薬 : (a)アルファ−アドレナリン作用薬:エフェドリン、エピネフリン、ノルフェ ネフリン、フェニレフリン、及びフェニルプロパノールアミン。 (b)ベーターアドレナリン作用薬:バムブテロール(bambuterol)、ビトテロ ール(bitoterol)、カルブテロール(carbuterol)、クレンブテロール、エフ ェドリン、フォルモテロール(formoterol)、ヘキソプレナリン、イソプロテレ ノール、マブテロール、ピルブテロール、レプロテロール(reproterol)、リミ テ ロール(rimiterol )、テルブタリン、及びトロブテロール。抗コリン作用性気管支拡張薬 :テレンゼピン(telenzepine)、トロベントール (troventol)、及びフルブロン。アルカロイド :アトロピン、スコポラミン、及びブロモクリプチン。 本発明に用いる薬剤は、フリー塩基、又は、医薬として許容される、非毒性の それらの塩の形態であるのがよい。好ましい塩として、薬学界又は医学界で既知 のもので挙げられる。ある特定の塩の選択は、塩基の化学的性質並びに製剤中の 塩の化学的安定性及び溶解度に依存する。用いることができる塩の例として、酢 酸塩、ベンゼンスルホン酸塩、安息香酸塩、ビカルボン酸塩、ビ酒石酸塩、臭化 物、カルシウム・エデンテート(calciumedentate)、カムシレート(camsylate )、エシレート(esylate)、フマル酸塩、フルセプテート(fluceptate)、グ ルコン酸塩、グルタミン酸塩、グリコールアーサニレート(glycolarsanilate) 、ヘキシルレゾルシナート(hexylresorcinate)、臭化水素酸塩、塩酸塩、ヒド ロキシナフトエート(hydroxynaphthoate)、ヨウ化物、イセチオナート(iseth ionate)、乳酸塩、ラクトビオナート(lactobionate)、リンゴ酸塩、マレイン 酸塩、マンデル酸塩(mandelate)、メシレート(mesylate)、メチル臭化物、 メチル硝酸塩、メチル硫酸塩(methysulfate)、ムチン酸塩(mucate)、ナプシ レート(napsylate)、硝酸塩、パモエート(pamoate)(エンボネート (embona te))、パントテン酸塩(pantothenate)、リン酸/ジリン酸塩、ポリガラクト ロネート(polygalacturonate)、サリチル酸塩、ステアリン酸塩、サブアセテ ート(subacetate)、コハク酸塩、硫酸塩、タンニン酸塩、酒石酸塩、及びトリ エチオダイド(triethiodide)が挙げられる。陽イオン性塩も用いることができ る。陽イオン性塩の例として、アルカリ金属、例えばナトリウム及びカリウム、 アンモニウム塩、並びに医薬として許容されると知られているアミンの塩、例え ばグリシン、エチレンジアミン、コリン、ジエタノールアミン、トリエタノール アミン、オクタデシルアミン、ジエチルアミン、トリエチルアミン、1-アミノ− 2-プロパノールーアミノ−2-(ヒドロキシメチル)プロパン−1,3-ジオール、及 び1-3(3,4-ジヒドロキシフェニル)−2-イソプロピルアミノエタノールが挙げ られる。 薬剤の化学的性質は補助溶剤の性質によって決まり、その補助溶剤は毒物学的 に安全であり、かつMDI溶液製剤に受け入れられる、多くの有機溶媒のうちの いかなる1つであってもよい。『補助溶剤』によって、製剤中で所望量で混和可 能であって、それを添加すると、薬剤を治療上有効量で溶解できる製剤を提供す る、いかなる溶媒をも意味する。製剤の薬剤と相互作用することが可能なヒドロ キシル機能基(又は他の機能基)を含む補助溶剤の例として、アルコール、例え ばエチルアルコール及びイソプロピルアルコール;グリコール、例えばプロピレ ングリコール、ポリエチレングリコール、ポリプロピレングリコール、グリコー ルエーテル、及びオキシエチレンとオキシプロピレンとのブロック共重合体;並 びに、他の物質、例えばグリセロール、ポリオキシエチレンアルコール、及びポ リオキシエチレン脂肪酸エステルが挙げられる。 薬剤との相互作用に不活性である補助溶剤の例として、炭化水素、例えばn-プ ロパン、n-ブタン、イソブタン、n-ペンタン、イソペンタン、ネオペンタン、及 びn-ヘキサン;並びに、エーテル、例えばジエチルエーテルが挙げられる。 本発明の好ましい補助溶剤はエチルアルコール(エタノール)である。 補助溶剤の機能は、製剤中の薬剤及び賦形剤の溶解度を高めることにある。よ って、製剤中に存在する補助溶剤の量は、ある特定の温度で溶解できる薬剤及び 賦形剤の最大量を決定する。 本発明のエアーゾル溶液製剤中の酸の選択は、用いる薬剤及び薬剤の崩壊の許 容できる速度を達成するのに必要な酸の濃度に依存する。理想的には、好ましい 酸は、もしあるならば、薬剤中に含まれるものと同じアニオンを有するものがよ いであろう。しかし、ある場合には、これには溶解度の限界があるかもしれない 。酸は、いかなる無機酸又は鉱酸、例えば塩酸、硫酸、硝酸、又はリン酸などで あってよい。また、酸を、有機酸として当業者に既知の酸の群から選択してもよ い。有機酸はほとんどの場合において、無機酸と比較して弱酸であると考えられ る。この群の代表的なもので、かつ本発明で好ましいものとして、アスコルビン 酸及びクエン酸が挙げられる。但し、他の有機酸も好適である。しかし、本発明 によると、MDI成分との適合性から、クエン酸が最も好ましい酸である。 本発明によると、ある特定の薬剤を含有するエアーゾル溶液製剤は、上記の群 のいずれかから選択される酸を用いて製剤されるのがよい。 製剤に酸を導入するのに用いる方法には、(1)無機酸又は有機酸を直接添加 する;(2)酸性塩として薬剤を添加し、それによってその場で(in situ)ある ベき酸性レベルにする;並びに、(3)(1)及び(2)の組合せ;が挙げられる 。薬剤を製剤に導入するのに適切な塩は当業者にとって明らかであろう。 実験室での研究により、HFC-134(a)及び約35%エタノール中の臭化イプラ トロピウムのエアーゾル溶液製剤が、50℃で貯蔵すると、臭化イプラトロピウ ムが著しく分解することが例証された。分解は、酸化、化学的脱水、加水分解、 及びエステル化に帰するものである。しかし、トロパ酸エチルエステルが主崩壊 生成物である。このエステルは、エタノールを臭化イプラトロピウムと直接反応 させることにより、又は、臭化イプラトロピウムの加水分解の次にトロパ酸とエ タノールとのエステル化により、形成することができる。水を1%添加すると、 脱水による分解が減少した。窒素雰囲気下で反応を行うと酸化生成物が減少した 。 水溶液中での加水分解及びエステル化の速度は典型的にはpHに依存する。水 溶液中、臭化イプラトロピウムの崩壊はpH3.5で最小pH速度を示す。これ は水素イオン濃度3.2×10-4モル(M)に対応する。pHの概念は非水溶液 系にはほとんど定義できないが、臭化イプラトロピウムを含むHFC-134(a)/エ タノール系中の塩酸のこの濃度を用いて製剤評価研究を行った。50℃で5.5 カ月間貯蔵したサンプルは、臭化イプラトロピウムを5.5%未満欠失した。こ れらの結果を図1にまとめて示した。 臭化イプラトロピウム、HFC-134(a)、及び塩酸、硝酸、リン酸、又は硫酸の ような無機酸を含むエアーゾル溶液製剤に対しての化学組成物の範囲を表1に示 す。製剤中に存在するアルコールの量は、ある特定の温度で溶解できる臭化イプ ラトロピウムの最大量で定義する。表1の臭化イプラトロピウムの濃度範囲は、 あるアルコール濃度に対して、室温で沈澱なく安全に溶解できる最大量に基づく 。酸含有量は、水溶液系で2.0−4.7に当たるpH範囲である規定度で与えら れている。 臭化イプラトロピウム、HFC-134(a)、及び有機酸、即ちアスコルビン酸を含 むエアーゾル溶液製剤に対しての化学組成物の範囲を表2に示す。表2に示した アスコルビン酸濃度の範囲はその酸解離定数pKa、及び水溶液系中の安定した 臭化イプラトロピウム製剤の最適なpH範囲(2.0−4.7)に基づく。アスコ ルビン酸では、水溶液pH範囲2.0−4.7に対応して0.0045−275m g/mlが必要である。しかし、アスコルビン酸は無水エタノールに約20mg /mlしか溶解せず、無水エタノール/HFC-134(a)系ではさらに溶解度が低い ものと予想されるという事実による、製剤の溶解度の限界も考慮に入れなければ ならない。表2に含まれる情報にはアスコルビン酸についてと、臭化イプラトロ ピウムの室温での溶解度と予想されるものに基づくエタノール含量の範囲を示す 。最適には、アスコルビン酸約0.30g/mlが、そのような製剤中に必要で あると予想され、 この値は水溶液系での臭化イプラトロピウムに対して最小pH崩壊速度であるp H3.5に対応する。 アスコルビン酸について表2に示された濃度範囲は、有機酸の酸解離定数に依 存するため、他の有機酸に対しては異なるものとなるであろう。例えば、クエン 酸約0.0039−27.7mg/mlが、臭化イプラトロピウムに対し最適水溶 性pH範囲である2.0−4.7に対応する、製剤中に必要な値であろう。 主に非水溶液エアーゾル製剤中の薬剤の許容される分解速度をもたらす酸濃度 範囲は、主に製剤の化学組成物(補助溶剤の選択や存在する薬剤の化学的性質) に依存する。この範囲は、無機酸では約0.10−0.0000001規定である と予想され、水溶性pH範囲約1.0−7.0に対応し、有機酸ではそのpKa値 に依存して計算しなけばならない。 臭化イプラトロピウム、HFC-134(a)、及びクエン酸を含むエアーゾル溶液製 剤についての化学組成物の好ましい実施例を表3に示した。有効投与量を供給す ると考えられる、MDI中の臭化イプラトロピウムの標準量を『標準強度』で示 した。しかし、半分の強度及び2倍強度の投与も好ましい。表3に示したクエン 酸濃度の範囲は、その酸解離定数pKa及び水溶液系の安定な臭化イプラトロピ ウム製剤の最適pH範囲(2.0−4.7)に基づいた。 他の好ましい実施例として、表4に、臭化水素酸フェノテロール、HFC-134(a )、及びクエン酸を含むエアーゾル製剤についての化学組成物を示す。 MDIバルブを通して導入できるエアーゾル溶液製剤中の薬物の量は、製剤中 の有効成分濃度(mg/ml)及びバルブの計量体積(μl)に依存するであろ う。一般に用いられるバルブのサイズは25、50、63、100μlである。 薬剤のエアーゾル溶液製剤を含む計量服用吸入器は、多くの従来の製造方法を 用いて製造することができる。1つの方法には、実験室での小規模実験ロットの 製造に有用なものであるが、デュアル・ステージ・プレッシャー・フィル(Dual Stage Pressure Fill)がある。この方法を、50μlバルブを用いる、2つの 特定の臭化イプラトロピウム溶液製剤について、表3及び表4に示す。大規模製 造のための2つの方法は、シングル・ステージ・コールド・フィル(Single-Sta ge Cold Fill)及びシングル・ステージ・プレッシャー・フィル(Single-Stage Pressure Fill)である。 II.装置成分 好適なエアーゾル容器 50μlエアーゾル計量バルブ III.製造方法の簡単な説明 1水和物としての臭化イプラトロピウム、硝酸、及び水をエチルアルコールに 溶解することにより、有効成分濃縮物を調製する。濃縮物を適当な充填器具に添 加する。有効成分濃縮物をエアーゾル容器に加える。容器の頭部に窒素又はHFC- 134(a)気体をパージして(パージする成分には酸素を1ppm以上含むべきで はない)、バルブでシールする。HFC-134(a)噴出剤をその後シールした容器に 圧縮充填する。 II.装置成分: 好適なエアーゾル容器 50μlエアーゾル計量バルブ III.製造方法の簡単な説明 1水和物としての臭化イプラトロピウム、アスコルビン酸、及び水をエチルア ルコールに溶解することにより、有効成分濃縮物を調製する。濃縮物を適当な充 填器具に添加する。有効成分濃縮物をエアーゾル容器に加えて、容器の頭部に窒 素又はHFC-134(a)気体をパージして(パージする成分には酸素を1ppm以上 含むべきではない)、バルブでシールする。HFC-134(a)噴出剤をその後シール した容器に圧縮充填する。DETAILED DESCRIPTION OF THE INVENTION Stabilized Medical Aerosol Solution Formulation This application is a continuation-in-part application of application number 07 / 987,852 (filing date Dec. 9, 1992). The present invention relates to stable pharmaceutical solution formulations suitable for aerosol administration. In particular, the present invention provides an aerosol solution formulation containing an agent containing an environment-safe hydrofluorocarbon (HFC) as a propellant together with an organic compound as a co-solvent, which contains a drug in a solution, and an inorganic acid or an organic acid added to the solution. To a stable pharmaceutical solution formulation suitable for. The acid provides stability against disintegration or decomposition of the drug primarily resulting from the interaction of the drug with co-solvents and / or water present in the solution formulation. BACKGROUND OF THE INVENTION Administering an aerosol formulation of a drug via a compressed, metered dose inhaler (MDI) is widely used in treatments such as obstructive airways and asthma. Compared to oral administration, inhalation has a faster onset of action while minimizing systemic side effects. Aerosol formulations can be administered by inhalation by the mouth or by application to the mucous membranes of the nose. Formulations for aerosol administration by MDI can be solutions or suspensions. Solution formulations offer the advantage of homogeneity due to the nature of the drug and excipients being completely soluble in the jetting solvent. In addition, solution formulations obviate the physical stability problems associated with suspension formulations, eliminating the need for surfactants while ensuring a more consistent and consistent dosage. Administration of aerosol solution formulations by MDI depends on the propellant force of the propellant system used to make them. Traditionally, propellants contain chlorofluorocarbon (CFC) mixtures to provide the desired solubility, pressure, and formulation stability. However, recently it has been established that CFCs are harmful to the environment as they contribute to the depletion of the earth's ozone layer, so instead of the environmentally damaging CFC propellants in aerosol inhalation formulations, environmentally safe hydrofluorocarbons have been replaced. Replacement with (HFC) propellants or other non-chlorinated propellants is desirable. For example, U.S. Pat. No. 4,174,295 discloses a combination of HFCs suitable for applications in the field of household products such as hair lacquers, perspiration resistant products, fragrances, deodorants, paints, insecticides, etc. The use of a propellant system consisting of components may also be included). It is known in the art that certain HFCs have suitable properties for use as propellants for air delivery of drugs. For example, published European patent application 0 372 777 (EP0 89312270.5) discloses that 1,1,1,2-tetrafluoroethane (HFC-134 (a)) is added to at least one "adjuvant" (HFC-134 ( It is described to be used in combination with a) more polar compounds) and surfactants to prepare suspensions and solution formulations of the drug suitable for administration by the aerosol route. In addition, PCT International Application WO 91/11496 (PCT / E P91 / 00178) discloses 1,1,1,2,3,3,3-, which is useful for preparing a suspension aerosol formulation of a drug. The use of heptafluoropropane (HFC-227), optionally mixed with other propellants, is described. It has now been found that the use of a propellant system containing HFC and a co-solvent in an aerosol solution formulation presents a chemical stability problem that was previously unrecognized or not solved by the prior art. It was This is due to the fact that in such HFC propellant / co-solvent systems, the drug may interact with co-solvents and / or water present in the system, resulting in decomposition or disintegration of the product. It has further been found that the addition of acids, either inorganic or organic, to the HFC propellant / cosolvent system provides the drug with the requisite chemical stability. DESCRIPTION OF THE INVENTION The term "aerosol suspension formulation" means a pharmaceutical formulation of a drug suitable for aerosol administration, in which the drug is suspended in the vehicle in the form of fine particles. The term "aerosol solution formulation" means a pharmaceutical formulation of a drug suitable for aerosol administration, in which the drug and the excipient are completely dissolved. The term "stabilized aerosol solution formulation" means an aerosol solution formulation that exhibits substantial chemical stability over time. Ipratropium bromide is an anticholinergic bronchodilator on the market under the trademark "ATROVENT". The drug is administered as an aerosol suspension formulation containing a mixture of CFC (dichlorodifluoromethane, dichlorotetrafluoroethane, and trichloromonofluoromethane) and soy lecithin as a propellant. Studies have shown that by dissolving ipratropium bromide in a homogeneous system containing HFC-134 (a), ethanol, and either an inorganic or organic acid, a stabilized aerosol solution formulation of ipratropium bromide can be obtained. Was done. By adding a certain type and amount of acid to the system, it would be possible to define the level of acidity that is important for obtaining a stable solution formulation. Thus, the present invention provides a stabilized aerosol solution formulation containing a drug, an HFC propellant, a co-solvent, and an inorganic or organic acid. A small amount of water (up to about 5% by weight) may be present in the propellant / cosolvent system. Suitable HFC propellants are those which, when mixed with a co-solvent, form a homogeneous propellant system in which a therapeutically effective amount of the drug can be dissolved. The HFC propellant must be toxicologically safe and have a suitable atmospheric pressure so that the drug can be administered by compressed MDI. In addition, the HFC propellant must be compatible with the components of the MDI device used to administer the drug (such as containers, valves, sealing gaskets, etc.). Preferred HFC propellants include 1,1,1,2-tetrafluoroethane (HFC-134 (a)) and 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) . HFC-134 (a) is particularly preferred. Other examples of the HFC-C propellant include HFC-32 (difluoromethane), HFC-143 (a) (1,1,1-trifluoroethane), HFC-134 (1,1,2,2-tetrafluoro). Ethane) and HFC-1 52a (1,1-difluoroethane). It will be apparent to those skilled in the art that non-halogenated hydrocarbon propellants may be used in place of HFC propellants in the present invention. Examples of non-halogenated hydrocarbons include saturated hydrocarbons including propane, n-butane, and isobutane, and ethers including diethyl ether. Although it is preferred to use only one HFC propellant, a mixture of two or more HFC propellants, or a mixture of at least one HFC propellant and one or more non-CFC propellants is used in the aerosol solution formulation of the present invention. It will be apparent to those skilled in the art that A substantially non-aqueous HFC propellant / cosolvent system is preferred. Water may be present in small amounts as an impurity in the HFC propellant / cosolvent system, introduced during the manufacturing process, or may penetrate into the system through a valve or valve / container seal or gasket. If desired, small amounts of water may be added to the HFC / propellant system (up to about 5% by weight), for example to aid production. If desired, pharmaceutically acceptable excipients may be included in the aerosol solution formulation of the present invention. For example, a soluble surfactant may be added to improve the performance of the valve system used in the MDI device used for aerosol delivery of the formulation. Examples of preferred surfactants include oleic acid, sorbitan trioleate, lecithin, and isopropyl myristate. Other suitable lubricants are known in the art (see, for example, Published European Patent Application 0372777 (EPO893122705)). Other excipients include (a) antioxidants such as ascorbic acid and tocopherols; (b) taste masking agents such as menthol, sweeteners, and artificial or natural flavors; and (c) pressure regulators such as n. -Pentane, isopentane, neopentane, and n-hexane. The drug used in the present invention may be any substance suitable for aerosol administration from an MDI or similar device. The drug must be soluble in the HFC propellant / cosolvent system and must exhibit significant disintegration or decomposition in the HFC propellant / cosolvent system. The disintegration or decomposition of the drug must be acid sensitive so that the rate of disintegration or decomposition can be effectively delayed by the addition of acid. Drug degradation or disintegration occurs by a variety of chemical mechanisms, the most important of which is the interaction of the drug with cosolvents or water present in the system, forming hydrolysis, esterification, and / or other products. To do. The amount of drug in the aerosol solution formulation of the present invention is an amount effective to bring about the intended therapeutic effect, that is, one or more metered volumes of the formulation will be an effective amount of the drug. It will be apparent to those skilled in the art that the effectiveness of a particular drug used in an aerosol solution formulation will depend on the amount of drug in the formulation. Generally, the drug is present in an amount of about 0.001 to 10 weight percent of the total weight of the formulation. Amounts of about 0.01 to 1.0 weight percent of the total weight of the formulation are preferred. Bronchodilators (particularly anticholinergic and sympathomimetic) are a preferred class of drugs for use in the aerosol solution formulations of the present invention. Those of ordinary skill in the art will recognize that other classes of agents may also be used in general. Examples of such classification include antihistamines, antiallergic agents, antiinflammatory agents, PAF antagonists, antitussives, antibiotics, mast cell stabilizers, mucolytics, antitumor agents, antiinfectives, vaccines, Anesthetics, diagnostic agents, analgesics, antianginal agents, leukotriene antagonists, and 5-lipoxygenase antagonists. Agents can also include various types of organic molecules including but not limited to hormones, enzymes, proteins, peptides, steroids, alkaloids, or combinations thereof. The most preferred example of the drug used in the aerosol solution formulation of the present invention is ipratropium bromide. Other preferred examples include oxitropium bromide (BA253), albuterol, me tapraterenol sulfate, tiotropium bromide (BA-679), 8 -Azoniabicyclo [3.2.1] oct-6-ene (8-azoniabicyclo [3.2.1] oct-6-ene), 3-[(hydroxydi-2-thienylacetyl) oxy] -8,8-dimethyl- ( 3-[(hydroxydi-2-thienylacetyl) oxy] -8,8-dimethyl-), chloride (chlori de), endo- (BEA 2108 CL) (endo- (BEA 2108 CL)), and fenoterol hydrobromide Is mentioned. Other examples of the drug include the following. Sympathomimetic bronchodilators : (a) Alpha-adrenergic: ephedrine, epinephrine, norphenephrine, phenylephrine, and phenylpropanolamine. (B) Beta-adrenergic agents: bambuterol, bitoterol, carbuterol, clenbuterol, ephedrine, formoterol, hesoprenaline, isoproterenol, mabuterol, pirbuterol, reproterol (reproterol), reproterol (reproterol). rimiterol), terbutaline, and trobuterol. Anticholinergic bronchodilators : telenzepine, troventol, and flubron. Alkaloids : atropine, scopolamine, and bromocriptine. The agents used in the present invention may be in the form of free bases or pharmaceutically acceptable non-toxic salts thereof. Preferred salts include those known in the pharmaceutical or medical arts. The choice of a particular salt depends on the chemical nature of the base and the chemical stability and solubility of the salt in the formulation. Examples of salts that can be used are acetates, benzenesulfonates, benzoates, bicarboxylates, bitartrates, bromides, calcium edentate, camsylate, esylate, fumaric acid. Salt, fluceptate, gluconate, glutamate, glycolarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, Isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl bromide, methyl nitrate, methylsulfate, mucin Acid salt (mucate), napsylate, nitrate, pamoe Pamoate (embona te), pantothenate, phosphoric acid / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate , Sulfates, tannates, tartrates, and triethiodides. Cationic salts can also be used. Examples of cationic salts are alkali metal salts such as sodium and potassium, ammonium salts, and salts of amines known to be pharmaceutically acceptable, such as glycine, ethylenediamine, choline, diethanolamine, triethanolamine, octadecylamine, Mention may be made of diethylamine, triethylamine, 1-amino-2-propanol-amino-2- (hydroxymethyl) propane-1,3-diol, and 1-3 (3,4-dihydroxyphenyl) -2-isopropylaminoethanol. The chemical nature of the drug depends on the nature of the cosolvent, which may be any one of many organic solvents that are toxicologically safe and acceptable for MDI solution formulations. By "co-solvent" is meant any solvent that is miscible in the formulation in the desired amount and, when added, provides a formulation in which the drug can be dissolved in a therapeutically effective amount. Examples of co-solvents containing hydroxyl functional groups (or other functional groups) capable of interacting with the drug of the formulation include alcohols such as ethyl alcohol and isopropyl alcohol; glycols such as propylene glycol, polyethylene glycol, polypropylene glycol, Included are glycol ethers and block copolymers of oxyethylene and oxypropylene; and other materials such as glycerol, polyoxyethylene alcohols, and polyoxyethylene fatty acid esters. Examples of cosolvents that are inert to drug interactions include hydrocarbons such as n-propane, n-butane, isobutane, n-pentane, isopentane, neopentane, and n-hexane; and ethers such as diethyl ether. Is mentioned. The preferred co-solvent of the present invention is ethyl alcohol (ethanol). The function of the co-solvent is to increase the solubility of the drug and excipients in the formulation. Thus, the amount of co-solvent present in the formulation will determine the maximum amount of drug and excipient that will be soluble at a particular temperature. The choice of acid in the aerosol solution formulation of the present invention depends on the drug used and the concentration of acid required to achieve an acceptable rate of drug disintegration. Ideally, the preferred acid, if any, would have the same anion as that contained in the drug. However, in some cases this may have solubility limitations. The acid can be any inorganic or mineral acid such as hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid. The acid may also be selected from the group of acids known to those skilled in the art as organic acids. Organic acids are considered to be weak acids in most cases compared to inorganic acids. Ascorbic acid and citric acid are typical of this group and preferred in the present invention. However, other organic acids are also suitable. However, according to the present invention, citric acid is the most preferred acid due to its compatibility with MDI components. According to the present invention, an aerosol solution formulation containing a particular drug may be formulated with an acid selected from any of the above groups. The methods used to introduce the acid into the formulation include (1) adding the inorganic or organic acid directly; (2) adding the drug as an acid salt, thereby producing a certain acidic in situ. Level, and a combination of (3), (1) and (2). Suitable salts for introducing the drug into the formulation will be apparent to those of skill in the art. Laboratory studies have demonstrated that an aerosol solution formulation of HFC-134 (a) and ipratropium bromide in approximately 35% ethanol undergoes significant degradation of ipratropium bromide when stored at 50 ° C. Degradation results from oxidation, chemical dehydration, hydrolysis, and esterification. However, tropic acid ethyl ester is the major degradation product. The ester can be formed by reacting ethanol directly with ipratropium bromide, or by hydrolysis of ipratropium bromide followed by esterification of tropic acid with ethanol. When 1% of water was added, decomposition due to dehydration was reduced. When the reaction was performed under a nitrogen atmosphere, the amount of oxidation products was reduced. The rates of hydrolysis and esterification in aqueous solution are typically pH dependent. In aqueous solution, the decay of ipratropium bromide shows a minimum pH rate at pH 3.5. This corresponds to a hydrogen ion concentration of 3.2 × 10 −4 mol (M). Although the concept of pH can hardly be defined for non-aqueous systems, formulation evaluation studies were conducted using this concentration of hydrochloric acid in HFC-134 (a) / ethanol system containing ipratropium bromide. Samples stored at 50 ° C for 5.5 months lacked less than 5.5% ipratropium bromide. The results are summarized in FIG. The range of chemical compositions for aerosol solution formulations containing ipratropium bromide, HFC-134 (a), and an inorganic acid such as hydrochloric acid, nitric acid, phosphoric acid, or sulfuric acid is shown in Table 1. The amount of alcohol present in the formulation is defined as the maximum amount of ipratropium bromide that can be dissolved at a particular temperature. The concentration range of ipratropium bromide in Table 1 is based on the maximum amount that can be safely dissolved at room temperature without precipitation for a given alcohol concentration. The acid content is given in a normality which is a pH range corresponding to 2.0-4.7 in an aqueous solution system. The ranges of chemical compositions for aerosol solution formulations containing ipratropium bromide, HFC-134 (a), and an organic acid, ascorbic acid, are shown in Table 2. The range of ascorbic acid concentrations shown in Table 2 is based on its acid dissociation constant pKa and the optimum pH range (2.0-4.7) of stable ipratropium bromide formulations in aqueous system. Ascorbic acid requires 0.0045-275 mg / ml corresponding to an aqueous pH range of 2.0-4.7. However, due to the fact that ascorbic acid dissolves only about 20 mg / ml in absolute ethanol and is expected to be even less soluble in the absolute ethanol / HFC-134 (a) system, the solubility limit of the formulation is taken into consideration. There must be. The information contained in Table 2 shows for ascorbic acid and the range of ethanol content based on the expected solubility of ipratropium bromide at room temperature. Optimally, about 0.30 g / ml of ascorbic acid would be required in such a formulation, this value being the minimum pH decay rate for ipratropium bromide in aqueous system pH 3.5. Corresponding to. The concentration range shown in Table 2 for ascorbic acid will be different for other organic acids as it depends on the acid dissociation constant of the organic acid. For example, about 0.0039-27.7 mg / ml of citric acid would be the required value in the formulation, corresponding to an optimal water-soluble pH range for ipratropium bromide of 2.0-4.7. The acid concentration range that results in the acceptable rate of degradation of the drug, primarily in non-aqueous aerosol formulations, depends primarily on the chemical composition of the formulation (the choice of cosolvent and the chemical nature of the drug present). This range is expected to be about 0.10-0.000001 for inorganic acids and corresponds to a water-soluble pH range of about 1.0-7.0, calculated for organic acids depending on its pKa value. I have to do it. A preferred example of the chemical composition for an aerosol solution formulation containing ipratropium bromide, HFC-134 (a), and citric acid is shown in Table 3. The standard amount of ipratropium bromide in MDI, which is thought to provide an effective dose, is indicated by "standard strength". However, half strength and double strength administrations are also preferred. The range of citric acid concentration shown in Table 3 was based on its acid dissociation constant pKa and the optimum pH range (2.0-4.7) of a stable aqueous ipratropium bromide formulation. As another preferred example, Table 4 shows the chemical composition for an aerosol formulation containing fenoterol hydrobromide, HFC-134 (a), and citric acid. The amount of drug in the aerosol solution formulation that can be introduced through the MDI valve will depend on the concentration of active ingredient in the formulation (mg / ml) and the metered volume of the valve (μl). Commonly used valve sizes are 25, 50, 63 and 100 μl. A metered dose inhaler containing an aerosol solution formulation of a drug can be manufactured using many conventional manufacturing methods. One method, which is useful for the production of small experimental lots in the laboratory, is the Dual Stage Pressure Fill. This method is shown in Tables 3 and 4 for two specific ipratropium bromide solution formulations using a 50 μl valve. Two methods for large scale manufacturing are Single-Stage Cold Fill and Single-Stage Pressure Fill. II. Equipment components Suitable aerosol container 50 μl Aerosol metering valve III. Brief Description of Manufacturing Method An active ingredient concentrate is prepared by dissolving ipratropium bromide as a monohydrate, nitric acid, and water in ethyl alcohol. Add the concentrate to a suitable filling device. Add the active ingredient concentrate to the aerosol container. Purge the head of the vessel with nitrogen or HFC-134 (a) gas (the components to be purged should not contain more than 1 ppm oxygen) and seal with a valve. The HFC-134 (a) propellant is then compression filled into a sealed container. II. Equipment components: Suitable aerosol container 50 μl aerosol metering valve III. Brief Description of Method of Preparation An active ingredient concentrate is prepared by dissolving ipratropium bromide as a monohydrate, ascorbic acid, and water in ethyl alcohol. Add the concentrate to a suitable filling device. The active ingredient concentrate is added to the aerosol container, the head of the container is purged with nitrogen or HFC-134 (a) gas (the purging component should not contain more than 1 ppm oxygen) and sealed with a valve. The HFC-134 (a) propellant is then compression filled into a sealed container.
───────────────────────────────────────────────────── フロントページの続き (81)指定国 EP(AT,BE,CH,DE, DK,ES,FR,GB,GR,IE,IT,LU,M C,NL,PT,SE),OA(BF,BJ,CF,CG ,CI,CM,GA,GN,ML,MR,NE,SN, TD,TG),AT,AU,BB,BG,BR,BY, CA,CH,CZ,DE,DK,ES,FI,GB,H U,JP,KP,KR,KZ,LK,LU,LV,MG ,MN,MW,NL,NO,NZ,PL,PT,RO, RU,SD,SE,SK,UA,UZ,VN (72)発明者 コントニー マーク ジェイ アメリカ合衆国 コネチカット州 06776 ニュー ミルフォード コーンウォール ドライヴ 19 (72)発明者 ナーゲル ユルゲン ハー ドイツ連邦共和国 デー6507 インゲルハ イム アム ライン タルシュトラーセ 142─────────────────────────────────────────────────── ─── Continued front page (81) Designated countries EP (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, M C, NL, PT, SE), OA (BF, BJ, CF, CG , CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, H U, JP, KP, KR, KZ, LK, LU, LV, MG , MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN (72) Inventor Contney Mark Jay Connecticut, United States 06776 New Milford Cornwall Drive 19 (72) Inventor Nagel Jürgen Ha Federal Republic of Germany Day 6507 Ingelha Im Am Rhein Tarstraße 142
Claims (1)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98785292A | 1992-12-09 | 1992-12-09 | |
US07/987,852 | 1992-12-09 | ||
US15354993A | 1993-11-22 | 1993-11-22 | |
US08/153,549 | 1993-11-22 | ||
US987,852 | 1993-11-22 | ||
US153,549 | 1993-11-22 | ||
PCT/US1993/011801 WO1994013262A1 (en) | 1992-12-09 | 1993-12-06 | Stabilized medicinal aerosol solution formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08509459A true JPH08509459A (en) | 1996-10-08 |
JP3009924B2 JP3009924B2 (en) | 2000-02-14 |
Family
ID=26850651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6514292A Expired - Fee Related JP3009924B2 (en) | 1992-12-09 | 1993-12-06 | Stabilized medical aerosol formulation |
Country Status (28)
Country | Link |
---|---|
US (3) | US5676930A (en) |
EP (1) | EP0673240B1 (en) |
JP (1) | JP3009924B2 (en) |
KR (1) | KR100312357B1 (en) |
AT (1) | ATE177941T1 (en) |
AU (2) | AU6048694A (en) |
BG (1) | BG62382B1 (en) |
BR (1) | BR9307627A (en) |
CA (1) | CA2151383C (en) |
CZ (1) | CZ284203B6 (en) |
DE (1) | DE69324161T2 (en) |
DK (1) | DK0673240T3 (en) |
ES (1) | ES2129117T3 (en) |
FI (1) | FI114283B (en) |
GB (1) | GB2288978B (en) |
GR (1) | GR3030529T3 (en) |
HK (1) | HK1011620A1 (en) |
HU (1) | HU221163B1 (en) |
LV (1) | LV10911B (en) |
NO (1) | NO311487B1 (en) |
NZ (1) | NZ259192A (en) |
PL (1) | PL177078B1 (en) |
RO (1) | RO117414B1 (en) |
RU (1) | RU2126248C1 (en) |
SG (1) | SG52459A1 (en) |
SK (1) | SK280911B6 (en) |
UA (1) | UA27143C2 (en) |
WO (2) | WO1994013263A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534266A (en) * | 2000-05-22 | 2003-11-18 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Stable pharmaceutical solution formulation for pressurized metered dose inhalers |
JP2004528305A (en) * | 2001-03-13 | 2004-09-16 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Compounds for treating inflammatory diseases |
JP2005505569A (en) * | 2001-09-18 | 2005-02-24 | ニコメド デンマーク エイピーエス | Composition for the treatment of the common cold |
JP2006504666A (en) * | 2002-06-12 | 2006-02-09 | エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー | Compositions, formulations and kits for treating respiratory and pulmonary diseases with dehydroepiandrosterone steroids and antimuscarinic agents |
JP2008537729A (en) * | 2005-02-25 | 2008-09-25 | チエシイ・ファルマセウテイシイ・エス・ペー・アー | Medicinal aerosol formulations containing sequestering agents for dose-measuring inhalers under pressure |
JP2011093915A (en) * | 2010-12-22 | 2011-05-12 | Chiesi Farmaceutici Spa | Stable pharmaceutical solution preparation for pressure-type quantitative inhalator |
JP2013515696A (en) * | 2009-12-23 | 2013-05-09 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Combination therapy for COPD |
JP2016539126A (en) * | 2013-11-22 | 2016-12-15 | テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド | Inhalable drug |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK280911B6 (en) * | 1992-12-09 | 2000-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical composition |
WO1996022081A1 (en) * | 1995-01-17 | 1996-07-25 | Omega Pharmaceutical, Incorporated | Liquid stable vitamin c compositions and delivery systems, and methods of making and uses thereof |
US5653961A (en) * | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
BR9604976A (en) * | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Metered dose inhaler metered dose inhaler system and use |
IL122752A (en) * | 1995-06-27 | 2001-07-24 | Boehringer Ingelheim Kg | Stable compositions for generating propellant-free aerosols |
DE19528145A1 (en) * | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | New drugs and their use |
US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
DE19653969A1 (en) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | New aqueous pharmaceutical preparation for the production of propellant-free aerosols |
US20030215396A1 (en) | 1999-09-15 | 2003-11-20 | Boehringer Ingelheim Pharma Kg | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
EP0954283B1 (en) | 1996-12-30 | 2007-03-21 | Battelle Memorial Institute | Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation |
CZ296966B6 (en) * | 1997-02-24 | 2006-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical composition |
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
GB2326334A (en) * | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
WO1999045777A1 (en) * | 1998-03-10 | 1999-09-16 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of asthma |
HU229064B1 (en) * | 1998-06-18 | 2013-07-29 | Boehringer Ingelheim Pharma | Pharmaceutical formulations for aerosols with two or more active substances |
DE19847968A1 (en) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
DZ2947A1 (en) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Pressure metered dose inhaler. |
GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
DE19921693A1 (en) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects |
US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
US20100197719A1 (en) * | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
ES2165768B1 (en) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
IT1313553B1 (en) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION. |
CA2317999C (en) | 1999-09-11 | 2004-11-09 | Glaxo Group Limited | Pharmaceutical formulation of fluticasone propionate |
ES2238334T3 (en) * | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | PHARMACEUTICAL FORMULATION IN SALMETEROL AEROSOL AND FLUTICASONA PROPIONATE. |
IT1317720B1 (en) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS. |
IT1317846B1 (en) * | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY. |
IT1318514B1 (en) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES. |
US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
MEP40008A (en) * | 2000-10-12 | 2011-02-10 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10063957A1 (en) * | 2000-12-20 | 2002-06-27 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and dopamine agonists |
US6620438B2 (en) * | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
US20020085978A1 (en) * | 2000-11-10 | 2002-07-04 | Mina Buenafe | Degradation-resistant glucocorticosteroid formulations |
US20100310477A1 (en) * | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
EP1241113A1 (en) | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
US6455028B1 (en) | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
AU2002303425A1 (en) * | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
EP1273292B1 (en) | 2001-07-02 | 2004-05-26 | CHIESI FARMACEUTICI S.p.A. | Optimised formulation of tobramycin for aerosolization |
DE10135355C1 (en) * | 2001-07-20 | 2003-04-17 | Schering Ag | Conjugates of macrocyclic metal complexes with biomolecules and their use in the preparation of NMR and radiodiagnostic agents and radiotherapy |
US8084461B2 (en) | 2001-10-26 | 2011-12-27 | Dey, L.P. | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
JP2003221335A (en) | 2001-10-26 | 2003-08-05 | Dey Lp | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease |
WO2003037317A1 (en) * | 2001-10-26 | 2003-05-08 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
AU3297402A (en) * | 2001-10-26 | 2003-10-30 | Dey, L.P. | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
DE10161368A1 (en) * | 2001-12-14 | 2003-07-10 | Messer Griesheim Gmbh | Cryogenic cooling of aerosol product mixtures, especially for filling pharmaceutical dosed aerosols, comprises controlled thermal contact with vaporized cooling gas in heat exchanger |
DE60231428D1 (en) | 2001-12-21 | 2009-04-16 | 3M Innovative Properties Co | MEDICAL AEROSOL COMPOSITIONS WITH A FUNCTIONALIZED POLYETHYLENE GLYCOL AGENT |
DE60228615D1 (en) | 2001-12-21 | 2008-10-09 | 3M Innovative Properties Co | MEDICAL AEROSOL COMPOSITIONS WITH AN EXCIPIENT COMPOUND CONTAINING AN AMID AND / OR ESTER GROUP |
JP2005514437A (en) * | 2001-12-21 | 2005-05-19 | スリーエム イノベイティブ プロパティズ カンパニー | Pharmaceutical aerosol formulations containing ion-pair complexes |
ATE465712T1 (en) | 2002-03-01 | 2010-05-15 | Chiesi Farma Spa | ULTRAFINE COMPOSITIONS OF FORMOTEROL |
US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
US7311894B2 (en) * | 2002-03-28 | 2007-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations containing an anticholinergic |
US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
WO2003099207A2 (en) * | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
CN1726038A (en) * | 2002-12-16 | 2006-01-25 | 贝林格尔英格海姆法玛两合公司 | Tiotropium containing HFC solution formulations |
US20050058606A1 (en) * | 2002-12-16 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing HFC solution formulations |
EP1915985A1 (en) * | 2003-03-20 | 2008-04-30 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants |
EA009087B1 (en) * | 2003-03-20 | 2007-10-26 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants |
US7273603B2 (en) * | 2003-07-11 | 2007-09-25 | Boehringer Ingelheim International Gmbh | HFC solution formulations containing an anticholinergic |
US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20090317476A1 (en) * | 2003-07-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
US20050101545A1 (en) * | 2003-07-31 | 2005-05-12 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
AR041873A1 (en) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | A PHARMACEUTICAL FORMULATION IN ADEQUATE AEROSOL FOR ORAL OR NASAL INHALATION CONTAINING GLUCOCORTICOIDS IN A STABLE SOLUTION TO STORAGE; A METHOD FOR STABILIZING FORMULATIONS AND USE OF A STABILIZING AGENT |
IL177103A0 (en) * | 2004-02-27 | 2006-12-10 | Chiesi Farma Spa | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
ES2257152B1 (en) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
PL1809243T5 (en) * | 2004-07-02 | 2022-12-27 | Boehringer Ingelheim International Gmbh | Aerosol suspension formulations containing tg 227 ea as a propellant |
GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
WO2006114379A1 (en) * | 2005-04-23 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent |
CN101166738B (en) | 2005-05-02 | 2011-06-01 | 贝林格尔·英格海姆国际有限公司 | Novel crystalline forms of tiotropium bromide |
KR101360803B1 (en) * | 2005-08-15 | 2014-02-11 | 베링거 인겔하임 인터내셔날 게엠베하 | Method for producing betamimetics |
WO2007034207A2 (en) * | 2005-09-25 | 2007-03-29 | Cipla Limited | Troventol formulation |
TWI396541B (en) * | 2005-10-10 | 2013-05-21 | Boehringer Ingelheim Int | Novel combinations of medicaments for the treatment of respiratory diseases |
US20070088030A1 (en) * | 2005-10-10 | 2007-04-19 | Barbara Niklaus-Humke | Aerosol formulations for the inhalation of beta-agonists |
DE102006017320A1 (en) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant |
DE102006023770A1 (en) * | 2006-05-20 | 2007-11-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Propellant-free aerosol formulation for inhalation |
WO2008008494A2 (en) * | 2006-07-13 | 2008-01-17 | Accentia Biopharmaceuticals, Inc. | Methods and compositions for treating mucosal inflammation |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2201934A1 (en) | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
EP2414560B1 (en) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Method for coating a surface of a component |
WO2010133294A2 (en) | 2009-05-18 | 2010-11-25 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
WO2011061498A2 (en) | 2009-11-17 | 2011-05-26 | Cipla Limited | Inhalation solutions |
CN102686260B (en) | 2009-11-25 | 2014-10-01 | 贝林格尔.英格海姆国际有限公司 | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
JP5658268B2 (en) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nebulizer |
US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
PE20121467A1 (en) | 2009-12-23 | 2012-11-07 | Chiesi Farma Spa | AEROSOL FORMULATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US20120204871A1 (en) | 2011-02-10 | 2012-08-16 | Julio Cesar Vega | Stable, non-corrosive formulations for pressurized metered dose inhalers |
WO2012130757A1 (en) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medical device comprising a container |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
GB201200504D0 (en) | 2011-12-19 | 2012-02-22 | Teva Branded Pharmaceutical Prod R & D Inc | An inhaler |
JP6335798B2 (en) * | 2012-02-28 | 2018-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New propellant-containing tiotropium formulation |
WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
RU2496477C1 (en) * | 2012-09-20 | 2013-10-27 | Шолекс Девелопмент Гмбх | Ipratropium bromide solution |
ES2836977T3 (en) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizer |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
RU2536253C1 (en) * | 2013-10-09 | 2014-12-20 | Шолекс Девелопмент Гмбх | Combined aerosol preparation for treating respiratory diseases |
TR201802607T4 (en) | 2013-11-22 | 2018-03-21 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable drug. |
ES2874029T3 (en) | 2014-05-07 | 2021-11-04 | Boehringer Ingelheim Int | Nebulizer |
UA121114C2 (en) | 2014-05-07 | 2020-04-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Nebulizer, indicator device and container |
EP3139979B1 (en) | 2014-05-07 | 2023-07-05 | Boehringer Ingelheim International GmbH | Unit, nebulizer and method |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
RU2577289C1 (en) * | 2015-03-26 | 2016-03-10 | Шолекс Девелопмент Гмбх | Aerosol preparation based on fenoterol hydrobromide for treating respiratory diseases |
CN114712337A (en) * | 2016-09-19 | 2022-07-08 | 墨西哥氟石股份公司 | Pharmaceutical composition |
EP3569221A1 (en) * | 2018-05-17 | 2019-11-20 | Notoxins IP B.V. | Aqueous formulations comprising ipratropium for topical treatment of hyperhidrosis |
WO2020152548A1 (en) * | 2019-01-24 | 2020-07-30 | Glenmark Pharmaceuticals Limited | Stable aerosol inhalation compositions of formoterol |
GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
CN111297835B (en) * | 2019-12-20 | 2022-11-25 | 上海方予健康医药科技有限公司 | Inhalation aerosol containing anticholinergic medicine and its preparation process and usage |
CN116419749A (en) * | 2020-10-09 | 2023-07-11 | 奇斯药制品公司 | Pharmaceutical formulation for pressurized metered-dose inhalers |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (en) * | 1956-03-21 | 1900-01-01 | ||
US3282781A (en) * | 1960-11-25 | 1966-11-01 | Merck & Co Inc | Inhalant compositions |
CA1178889A (en) * | 1980-08-28 | 1984-12-04 | Kenneth S. Su | Intranasal formulation |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8900267D0 (en) * | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
DE4003270A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS |
DE4003272A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS |
US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5190029A (en) * | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
PT656207E (en) * | 1991-06-10 | 2001-11-30 | Schering Corp | AEROSOLS FORMULATIONS WITHOUT CHLOROFLUOROCARBONETS |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
SK280911B6 (en) * | 1992-12-09 | 2000-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical composition |
US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
-
1993
- 1993-12-06 SK SK760-95A patent/SK280911B6/en not_active IP Right Cessation
- 1993-12-06 AU AU60486/94A patent/AU6048694A/en not_active Withdrawn
- 1993-12-06 BR BR9307627A patent/BR9307627A/en not_active Application Discontinuation
- 1993-12-06 KR KR1019950702333A patent/KR100312357B1/en not_active IP Right Cessation
- 1993-12-06 EP EP94903467A patent/EP0673240B1/en not_active Revoked
- 1993-12-06 RU RU95117235A patent/RU2126248C1/en active
- 1993-12-06 WO PCT/US1993/011856 patent/WO1994013263A1/en active Application Filing
- 1993-12-06 UA UA95073157A patent/UA27143C2/en unknown
- 1993-12-06 RO RO95-01110A patent/RO117414B1/en unknown
- 1993-12-06 HU HU9501663A patent/HU221163B1/en unknown
- 1993-12-06 DK DK94903467T patent/DK0673240T3/en active
- 1993-12-06 ES ES94903467T patent/ES2129117T3/en not_active Expired - Lifetime
- 1993-12-06 CZ CZ951490A patent/CZ284203B6/en not_active IP Right Cessation
- 1993-12-06 AU AU57405/94A patent/AU680227B2/en not_active Expired
- 1993-12-06 JP JP6514292A patent/JP3009924B2/en not_active Expired - Fee Related
- 1993-12-06 WO PCT/US1993/011801 patent/WO1994013262A1/en not_active Application Discontinuation
- 1993-12-06 PL PL93309333A patent/PL177078B1/en unknown
- 1993-12-06 GB GB9511669A patent/GB2288978B/en not_active Expired - Lifetime
- 1993-12-06 NZ NZ259192A patent/NZ259192A/en not_active IP Right Cessation
- 1993-12-06 DE DE69324161T patent/DE69324161T2/en not_active Revoked
- 1993-12-06 AT AT94903467T patent/ATE177941T1/en not_active IP Right Cessation
- 1993-12-06 CA CA002151383A patent/CA2151383C/en not_active Expired - Lifetime
- 1993-12-06 SG SG1996004813A patent/SG52459A1/en unknown
-
1995
- 1995-06-07 US US08/475,060 patent/US5676930A/en not_active Expired - Lifetime
- 1995-06-08 NO NO19952269A patent/NO311487B1/en not_active IP Right Cessation
- 1995-06-09 FI FI952842A patent/FI114283B/en not_active IP Right Cessation
- 1995-06-09 LV LVP-95-163A patent/LV10911B/en unknown
- 1995-06-29 BG BG99760A patent/BG62382B1/en not_active Expired - Lifetime
-
1997
- 1997-04-14 US US08/843,180 patent/US5955058A/en not_active Expired - Lifetime
-
1998
- 1998-12-07 HK HK98112913A patent/HK1011620A1/en not_active IP Right Cessation
-
1999
- 1999-05-03 US US09/303,610 patent/US6045778A/en not_active Expired - Lifetime
- 1999-06-16 GR GR990401605T patent/GR3030529T3/en unknown
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534266A (en) * | 2000-05-22 | 2003-11-18 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Stable pharmaceutical solution formulation for pressurized metered dose inhalers |
JP2004528305A (en) * | 2001-03-13 | 2004-09-16 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Compounds for treating inflammatory diseases |
US8450339B2 (en) | 2001-09-18 | 2013-05-28 | Takeda Pharma A/S | Compositions for treatment of common cold |
JP2005505569A (en) * | 2001-09-18 | 2005-02-24 | ニコメド デンマーク エイピーエス | Composition for the treatment of the common cold |
US7652030B2 (en) | 2001-09-18 | 2010-01-26 | Nycomed Danmark Aps | Compositions for treatment of common cold |
JP2006504666A (en) * | 2002-06-12 | 2006-02-09 | エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー | Compositions, formulations and kits for treating respiratory and pulmonary diseases with dehydroepiandrosterone steroids and antimuscarinic agents |
JP2008537729A (en) * | 2005-02-25 | 2008-09-25 | チエシイ・ファルマセウテイシイ・エス・ペー・アー | Medicinal aerosol formulations containing sequestering agents for dose-measuring inhalers under pressure |
JP2016145239A (en) * | 2009-12-23 | 2016-08-12 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Combination therapy for copd |
JP2013515696A (en) * | 2009-12-23 | 2013-05-09 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Combination therapy for COPD |
US10159645B2 (en) | 2009-12-23 | 2018-12-25 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
US11389401B2 (en) | 2009-12-23 | 2022-07-19 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
JP2011093915A (en) * | 2010-12-22 | 2011-05-12 | Chiesi Farmaceutici Spa | Stable pharmaceutical solution preparation for pressure-type quantitative inhalator |
JP2016539126A (en) * | 2013-11-22 | 2016-12-15 | テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド | Inhalable drug |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08509459A (en) | Stabilized medical aerosol solution formulation | |
EP1646364B1 (en) | Hfc solution formulations containing an anticholinergic | |
JP2786493B2 (en) | Pharmaceutical aerosol formulation | |
JP3323199B2 (en) | Aerosol formulation without chlorofluorocarbon | |
JP2003534266A (en) | Stable pharmaceutical solution formulation for pressurized metered dose inhalers | |
US20090175802A1 (en) | Tiotropium containing hfc solution formulations | |
HU214914B (en) | Packagings under pressurized gas using polyoxyethylene glyceryl-obates and process for producing thereof | |
JPH0770557A (en) | Aerosol pressure gas charge for applying biological active material and preparation thereof | |
KR20050085650A (en) | Tiotropium containing hfc solution formulations | |
CN1054282C (en) | Stabilized medicinal aerosol solution formulations | |
NZ243056A (en) | Aerosol formulation containing a medicament, tetrafluoroethane and isopropyl myristate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081203 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091203 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091203 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111203 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111203 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121203 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121203 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131203 Year of fee payment: 14 |
|
LAPS | Cancellation because of no payment of annual fees |